Tag: Gvhd

Used for decades in transplantation, Antithymocyte Globulin (ATG) is a powerful polyclonal antibody with a complex mode of action. Understanding precisely **what is the mechanism of action of ATG?** is crucial for its clinical application in preventing organ rejection and treating conditions like severe aplastic anemia.

Following an allogeneic bone marrow transplant (BMT), nearly all patients require immunosuppressive drugs to prevent complications. **How long do you take immunosuppressants after a bone marrow transplant** is not a simple question, as the timeline is highly individualized and dependent on factors like the type of transplant and the risk of graft-versus-host disease (GVHD).

Fever is listed among the more common side effects for patients taking Jakafi (ruxolitinib) [1.2.2]. So, can Jakafi cause fever? The answer is yes, and it is often a sign of the body's response to the medication or a potential infection [1.2.4].

In clinical trials for myelofibrosis, 42% of patients taking Jakafi saw their spleen volume reduce by at least 35% after 6 months [1.2.3, 1.4.2]. Understanding these metrics is key when asking, 'How do you know if Jakafi is working?'.

In a study of 251 myelofibrosis patients who discontinued Jakafi (ruxolitinib), 13.5% experienced a discontinuation syndrome [1.2.1]. Understanding what happens when you stop taking Jakafi is critical for patient safety and managing disease symptoms.

Following allogeneic stem cell transplantation, graft-versus-host disease (GVHD) remains a serious complication, and recent advancements have brought new hope. So, what is the new drug for GVHD? Actually, two distinct and groundbreaking therapies for both chronic and acute forms of the disease have been recently approved by the FDA.